MOUNTAIN VIEW, Calif., Jan. 6 ChemoCentryx, Inc., today announced that the executive management team will participate in the 28th Annual J.P. Morgan Healthcare Conference being held January 11 through January 14 in San Francisco at the Westin St. Francis Hotel.
Advertisement
Thomas J. Schall, Ph.D., ChemoCentryx's President and Chief Executive Officer, is scheduled to present an update of the company's pipeline progress and recent developments on Tuesday, January 12, 2010 at 4:30 p.m. Pacific Time.
Advertisement
About ChemoCentryx
ChemoCentryx, Inc., is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a network of secreted chemokine molecules, or ligands, and cell surface receptors that regulates inflammation. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has internally generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, Traficet-EN, a specific CCR9 antagonist, completed a Phase 2/3 multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease. CCX025, also a CCR9 antagonist, successfully concluded a Phase 1 clinical program. Additional clinical programs include CCX140, which targets the CCR2 receptor, expected to enter Phase 2 clinical development in the first quarter of 2010 for the treatment of type 2 diabetes mellitus, and CCX354, a CCR1 antagonist in a Phase 2 clinical trial for the treatment of rheumatoid arthritis. ChemoCentryx also has several programs in preclinical development. ChemoCentryx is privately held. For more information, please refer to www.chemocentryx.com.
SOURCE ChemoCentryx, Inc.
